Topiramate Tablet
Product Images NDC 70518-2419

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 70518-2419). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Topiramate 50 mg oral tablets packaged in a quantity of 30, labeled by RemedyRepack Inc. The label includes product information such as the NDC number 70518-2419-00, manufacturing details by Cipla Ltd, Kurkumbh, India, and storage directions. It also states 'RX ONLY' and references the package insert for directions for use.*

FDA Label Image

Mm2 (Topiramate 50mg 70518 2419 01)

Topiramate 50 mg tablet label showing a single tablet quantity. The label includes the product name, dosage strength, dosage form, and quantity. It is repackaged by RemedyRepack Inc. and originally manufactured by Cipla Ltd., Kurkumbh, India. The label contains a QR code, NDC number, and storage instructions.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 01

Chemical structure of Topiramate, showing its molecular framework with functional groups including sulfate and multiple oxygen atoms in a six-membered ring with attached methyl groups.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 02

A cumulative incidence curve comparing time to first seizure over 500 days for two Topiramate dosage groups: 50 mg/day and 400 mg/day. The graph plots cumulative rates on the vertical axis and time in days on the horizontal axis, showing a lower seizure rate in the 400 mg/day group compared to the 50 mg/day group, with a statistical p-value of 0.0002.*

FDA Label Image

Ccb7a1e4 A3a1 4a0e 8eb0 8086f53e314b 03

A bar chart displaying changes from baseline to double-blind phase in average monthly migraine periods per 28 days. The chart compares Placebo, Topamax 50 mg/day, Topamax 100 mg/day, and Topamax 200 mg/day across two studies (Study 10 and Study 11) with statistical significance indicated for higher doses.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.